Evidence map›Paper›PMID 34894011›Full record

ReviewJournal of clinical laboratory analysis2022

Coronavirus Disease 2019 (COVID-19): Emerging detection technologies and auxiliary analysis.

Ying Chen, Shengxiong Huang, Liuyan Zhou, Xin Wang, Huan Yang, Wenqing Li

Open access · goldAbstract readReview
In one paragraph

Review in Journal of clinical laboratory analysis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Can Digital PCR Enhance the Detection ofPathogens (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Ying ChenSchool of Medical Technology, Xuzhou Medical University, Xuzhou, China.
Shengxiong HuangSchool of Food and Biological Engineering, Hefei University of Technology, Hefei, China.
Liuyan ZhouSchool of Anesthesiology, Xuzhou Medical University, Xuzhou, China.
Xin WangCentralized and Point of Care Solutions & Molecular Diagnostics, Roche Diagnostics (Shanghai) Limited, Shanghai, China.
Huan YangSchool of Medical Technology, Xuzhou Medical University, Xuzhou, China.
Wenqing LiSchool of Medical Technology, Xuzhou Medical University, Xuzhou, China.
Xuzhou Medical College · CNHefei University of Technology · CNRoche (China) · CN

Funding

National Natural Science Foundation of China 81702103Projects for Jiangsu Provincial Young Medical Talents QNRC2016780Qinglan Project of Jiangsu Province of China
6 · The paper itself

Abstract

The ongoing COVID-19 pandemic constitutes a new challenge for public health. Prevention and control of infection have become urgent and serious issues. To meet the clinical demand for higher accuracy of COVID-19 detection, the development of fast and efficient methods represents an important step. The most common methods of COVID-19 diagnosis, relying on real-time fluorescent quantitative PCR(RT-qPCR), computed tomography, and new-generation sequencing technologies, have a series of advantages, especially for early diagnosis and screening. In addition, joint efforts of researchers all over the world have led to the development of other rapid detection methods with high sensitivity, ease of use, cost-effectiveness, or allowing multiplex analysis based on technologies such as dPCR, ELISA, fluorescence immunochromatography assay, and the microfluidic detection chip method. The main goal of this review was to provide a critical discussion on the development and application of these different analytical methods, which based on etiology, serology, and molecular biology, as well as to compare their respective advantages and disadvantages. In addition to these methods, hematology and biochemistry, as well as auxiliary analysis based on pathological anatomy, ultrasonography, and cytokine detection, will help understand COVID-19 pathogenesis. Together, these technologies may promote and open new windows to unravel issues surrounding symptomatic and asymptomatic COVID-19 infections and improve clinical strategies toward reducing mortality.

Indexed as

Chromatography, AffinityCOVID-19COVID-19 TestingCytokinesEnzyme-Linked Immunosorbent AssayFour-Dimensional Computed TomographyGold ColloidHumansMass SpectrometryNasopharynxPolymerase Chain ReactionSARS-CoV-2CytokinesGold Colloidauxiliary analysiscomparisonCOVID-19emerging technologiesSARS-CoV-2

Identifiers

PMID34894011
PMCPMC8761422
OpenAlexW4200105485

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.